A new class of VMAT-2 inhibitors for tardive dyskinesia

Affiliations

¹ The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Hofstra Northwell School of Medicine at Hofstra University, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin Institute of Health, Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy. Electronic address: ccorrell@northwell.edu.
² The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA.

Comment

Christoph U Correll et al. Lancet Psychiatry. 2017 Aug.

. 2017 Aug;4(8):574-575.

doi: 10.1016/S2215-0366(17)30279-1. Epub 2017 Jun 28.

¹ The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Hofstra Northwell School of Medicine at Hofstra University, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin Institute of Health, Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy. Electronic address: ccorrell@northwell.edu.
² The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA.

No abstract available

Comment on

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Anderson KE, et al. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. Lancet Psychiatry. 2017. PMID: 28668671 Clinical Trial.